Efficacy and safety of VPM1002 and Immuvac in preventing tuberculosis: phase 3 randomised clinical trial (PreVenTB trial)
Quick Take: A Phase 3 trial evaluating novel tuberculosis vaccine candidates in at-risk populations is an important step toward expanding TB prevention options, but clinical adoption depends on demonstrated efficacy, safety, and durability of protection in the reported outcomes.
💡 Clinical Impact
Mechanistic Why:
Recombinant BCG-based and mycobacterial immunotherapy candidates aim